Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Intraoral Vacuum-Assisted Closure Therapy-A Pilot Study in Medication-Related Osteonecrosis of the Jaw.

Laimer J, Steinmassl O, Hechenberger M, Rasse M, Pikula R, Bruckmoser E.

J Oral Maxillofac Surg. 2017 Oct;75(10):2154-2161. doi: 10.1016/j.joms.2017.02.033. Epub 2017 Mar 18.

PMID:
28396234
2.

Scaffold hopping approach towards various AFQ-056 analogs as potent metabotropic glutamate receptor 5 negative allosteric modulators.

Kubas H, Meyer U, Hechenberger M, Klein KU, Plitt P, Zemribo R, Spexgoor HW, van Assema SG, Abel U.

Bioorg Med Chem Lett. 2013 Dec 1;23(23):6370-6. doi: 10.1016/j.bmcl.2013.09.059. Epub 2013 Sep 29.

PMID:
24125886
3.

Discovery, synthesis, and structure-activity relationships of 2-aminoquinazoline derivatives as a novel class of metabotropic glutamate receptor 5 negative allosteric modulators.

Kubas H, Meyer U, Krueger B, Hechenberger M, Vanejevs M, Zemribo R, Kauss V, Ambartsumova R, Pyatkin I, Polosukhin AI, Abel U.

Bioorg Med Chem Lett. 2013 Aug 15;23(16):4493-500. doi: 10.1016/j.bmcl.2013.06.049. Epub 2013 Jun 25.

PMID:
23856046
4.

Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.

Dekundy A, Gravius A, Hechenberger M, Pietraszek M, Nagel J, Tober C, van der Elst M, Mela F, Parsons CG, Danysz W.

J Neural Transm (Vienna). 2011 Dec;118(12):1703-16. doi: 10.1007/s00702-010-0526-0. Epub 2010 Dec 16.

PMID:
21161716
5.

Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors.

Gilling KE, Jatzke C, Hechenberger M, Parsons CG.

Neuropharmacology. 2009 Apr;56(5):866-75. doi: 10.1016/j.neuropharm.2009.01.012. Epub 2009 Jan 21.

PMID:
19371579
6.

Positive and negative modulation of group I metabotropic glutamate receptors.

Vanejevs M, Jatzke C, Renner S, Müller S, Hechenberger M, Bauer T, Klochkova A, Pyatkin I, Kazyulkin D, Aksenova E, Shulepin S, Timonina O, Haasis A, Gutcaits A, Parsons CG, Kauss V, Weil T.

J Med Chem. 2008 Feb 14;51(3):634-47. doi: 10.1021/jm0611298. Epub 2008 Jan 4.

PMID:
18173231
7.

Virtual screening for selective allosteric mGluR1 antagonists and structure-activity relationship investigations for coumarine derivatives.

Noeske T, Jirgensons A, Starchenkovs I, Renner S, Jaunzeme I, Trifanova D, Hechenberger M, Bauer T, Kauss V, Parsons CG, Schneider G, Weil T.

ChemMedChem. 2007 Dec;2(12):1763-73.

PMID:
17868161
8.

Searching for drug scaffolds with 3D pharmacophores and neural network ensembles.

Renner S, Hechenberger M, Noeske T, Böcker A, Jatzke C, Schmuker M, Parsons CG, Weil T, Schneider G.

Angew Chem Int Ed Engl. 2007;46(28):5336-9. No abstract available.

PMID:
17604383
9.

The new voltage gated potassium channel KCNQ5 and neonatal convulsions.

Kananura C, Biervert C, Hechenberger M, Engels H, Steinlein OK.

Neuroreport. 2000 Jun 26;11(9):2063-7.

PMID:
10884071
10.

KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents.

Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, Jentsch TJ.

J Biol Chem. 2000 Aug 4;275(31):24089-95.

11.

Golgi localization and functionally important domains in the NH2 and COOH terminus of the yeast CLC putative chloride channel Gef1p.

Schwappach B, Stobrawa S, Hechenberger M, Steinmeyer K, Jentsch TJ.

J Biol Chem. 1998 Jun 12;273(24):15110-8.

12.

A family of putative chloride channels from Arabidopsis and functional complementation of a yeast strain with a CLC gene disruption.

Hechenberger M, Schwappach B, Fischer WN, Frommer WB, Jentsch TJ, Steinmeyer K.

J Biol Chem. 1996 Dec 27;271(52):33632-8.

13.

Supplemental Content

Loading ...
Support Center